Campbell & Co Investment Adviser’s Puma Biotechnology PBYI Stock Holding History

Campbell & Co Investment Adviser’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-20,400	Closed	-$143K	–	764
2021 Q3	$143K	Buy	+20,400	New	+$153K	0.05%	547
2020 Q1	–	Sell	-16,615	Closed	-$145K	–	374
2019 Q4	$145K	Buy	+16,615	New	+$138K	0.04%	614
2019 Q3	–	Sell	-19,638	Closed	-$250K	–	726
2019 Q2	$250K	Buy	+19,638	New	+$452K	0.11%	383

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Campbell & Co Investment Adviser's PBYI Position: Q4 2021 in Review

Campbell & Co Investment Adviser sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 20,400 shares — an estimated $143K sold.

Campbell & Co Investment Adviser first reported a position in PBYI in Q2 2019 and held it in 3 quarters. The position peaked at $250K in Q2 2019. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

Campbell & Co Investment Adviser reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
Campbell & Co Investment Adviser sold 20,400 Puma Biotechnology shares in Q4 2021, an estimated $143K.
Campbell & Co Investment Adviser first reported a position in Puma Biotechnology in Q2 2019 and held it in 3 quarters.
Campbell & Co Investment Adviser's Puma Biotechnology position peaked at $250K in Q2 2019.
102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2021, filed 10 Feb 2022.